The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients.
about
Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burdenTherapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesPatients with rheumatoid arthritis have an altered circulatory aggrecan profile.Searching for potential biomarkers that can be used as biomarkers for diagnosing ankylosing spondylitis.Predictors of outcome after 6 and 12 months following anthroposophic therapy for adult outpatients with chronic disease: a secondary analysis from a prospective observational study.Usefulness of a centralized system of data collection for the development of an international multicentre registry of spondyloarthritis.Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Clinical Case Registries: simultaneous local and national disease registries for population quality management.International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisChanges in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000sClinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.Staging of patients with ankylosing spondylitis: a preliminary proposalOverview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis.Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group.[How do register data support clinical decision-making?].Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the patient perspective using focus groups.Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in GermanyOverview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys.Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012.Progesterone and autoimmune disease.Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis.Definition of disease duration in ankylosing spondylitis: reassessing the concept.Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review.Modulation of autoimmune rheumatic diseases by oestrogen and progesterone.Disease patterns of rheumatology outpatients seen in a tertiary hospital serving a multi-ethnic, urban Asian population in Singapore.Anti-TNF agents for the treatment of spondyloarthropathies.Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.Individual interviews and focus groups in patients with rheumatoid arthritis: a comparison of two qualitative methods.Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres.Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.Effects of tumor necrosis factor inhibitor on serum level of HLA-B27 and PDCD-1 in patients with ankylosing spondylitis.Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore.Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis.Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
P2860
Q22255575-C7E44CA2-451B-4E23-895C-86F8FCD5956DQ24806367-7C56EB44-633A-4B0F-8C11-58F659F84030Q33338239-A8E7C2A5-AE3F-45DF-8B71-34D6CFC57F21Q33579369-4F6C1D15-5384-40AF-83D7-02DD1073D453Q33648486-317D89D1-A655-4878-824D-C69D5C196835Q33686605-D3877534-6869-4AE3-94F7-4D09DDB070B9Q33766318-09BDF7F7-A5EA-4F2B-B852-52E3FA0C700AQ34407096-88C2DDB3-BB3A-46E7-ACF9-8176FED4DFDFQ34536278-852D4E2B-53A0-4012-AA1F-D47141212B8FQ34739465-D47A4904-F5AE-4367-81B6-FFD1E989055EQ34897423-2065BC84-84A1-45F0-95F8-93F74F812626Q34967499-4FB8EC29-E014-4608-A050-50541A7A8ABDQ35116177-D64E3D26-F929-4865-A5E5-D26A2A8A58C5Q35164736-7DB598F9-62BF-4DF2-AE6E-09C2BC70E6ACQ35550175-C4886577-5214-4242-AF70-43E6EFA5E0A0Q35553066-E0CEE4ED-22DB-4AE8-B083-C4D5C540CBE0Q35585867-FA62AF85-32AB-47E4-92A2-1D226EE1DA53Q35605617-7E5DBE7C-1D24-4F46-8927-C23C99CAC95CQ35637894-CE0D661E-9D9E-45D7-997B-D2F79970CB9EQ35799592-0088AF57-CFF0-444A-9D23-2ECCFAD88F30Q36182303-6344D73B-4D0E-48AD-88AC-8B3187922054Q36202227-7B748918-330C-48D8-99DF-0A4CE30B893CQ36245711-9C8E336E-EC58-4AF5-9CA6-78ECB47297EFQ36275101-26BF223E-BE8B-4292-AACD-0C6026F3C54DQ36365524-FC597936-6A37-4D48-B300-606A51EEA88CQ36390174-5AA53EE4-258E-4C86-90BF-0061EE5EE919Q37358286-0BDCC80C-43A0-4102-8A38-186E16F77962Q37729028-155C9D56-DFB6-42A9-B2AF-E551367C0906Q38217664-ED884B22-7B49-4129-9A14-D963C47E9E53Q38243118-F135222C-442F-4627-890C-0C0F934D0B47Q40133444-25264668-B7AC-47FC-A78C-A421D17BCE63Q40409369-3E43B001-9757-4D80-AD87-873A5F593DD7Q41912381-84CF1A61-5C4D-4C93-B6E2-703B31D963FEQ42606767-06EC272B-372D-4AC2-839B-7ED4391382DCQ44089331-B5475752-ABE0-4078-955C-42468C672196Q46456972-B035BAF3-0274-45A2-98F3-B2DB4C2445F9Q46485224-9030D6F6-8408-46C4-8AC8-53A300DBD617Q48330154-162292AA-C37D-42AB-9DDD-A3DFC9F0E20EQ52887127-4DDD25C2-029F-459F-80CB-489C87409F5CQ53305562-A3B76159-A1F3-4FB3-9A46-0762F4F6B5B4
P2860
The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The national database of the G ...... Structure, aims, and patients.
@ast
The national database of the G ...... Structure, aims, and patients.
@en
type
label
The national database of the G ...... Structure, aims, and patients.
@ast
The national database of the G ...... Structure, aims, and patients.
@en
prefLabel
The national database of the G ...... Structure, aims, and patients.
@ast
The national database of the G ...... Structure, aims, and patients.
@en
P2093
P2860
P356
P1476
The national database of the G ...... Structure, aims, and patients.
@en
P2093
C Klindworth
German Collaboratrive Arthritis Centres
P2860
P304
P356
10.1136/ARD.60.3.199
P407
P577
2001-03-01T00:00:00Z